VIM and cancer: Consistently, PLX3397 + TMZ + PL or PLX3397 + TMZ + SAHA therapy significantly suppressed G422TN-cell proliferation (decreased Ki-67+ numbers, Fig. 7E, F) and invasion (decreased vimentin expression, Fig. 7G, H), while increased G422TN-cell apoptotic death (increased cleaved-caspase3+ cells, Fig. 7I, J) and anti-cancer immunity (increased CD3+ T cells, Fig. 7K, L) in G422TN-tumors compared to PLX3397 + TMZ group.